GMC 283

Drug Profile

GMC 283

Latest Information Update: 18 Jan 2001

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lundbeck A/S; Merck KGaA
  • Class Antipsychotics; Dibenzazepines; Small molecules
  • Mechanism of Action Dopamine D1 receptor antagonists; Dopamine D2 receptor antagonists; Serotonin 2A receptor antagonists; Serotonin 2C receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Schizophrenia

Most Recent Events

  • 18 Jan 2001 Discontinued-Preclinical for Schizophrenia in Netherlands (Unknown route)
  • 14 Dec 1999 New profile
  • 14 Dec 1999 Preclinical development for Schizophrenia in Netherlands (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top